Septerna (NASDAQ:SEPN) Rating Lowered to “Hold” at Wall Street Zen

Septerna (NASDAQ:SEPN) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research report on Thursday, January 22nd. Raymond James Financial assumed coverage on shares of Septerna in a research note on Friday, December 19th. They issued a “strong-buy” rating and a $38.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $60.00 target price on shares of Septerna in a report on Tuesday. HC Wainwright increased their target price on Septerna from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Finally, Truist Financial lifted their price target on Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $44.00.

Septerna Trading Down 4.9%

Shares of Septerna stock opened at $25.14 on Friday. The stock’s fifty day moving average price is $26.78 and its 200-day moving average price is $23.39. The firm has a market cap of $1.13 billion, a P/E ratio of -22.65 and a beta of 3.46. Septerna has a 12 month low of $4.66 and a 12 month high of $32.63.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Monday, March 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). Septerna had a negative return on equity of 15.85% and a negative net margin of 106.37%.The business had revenue of $24.12 million during the quarter, compared to analysts’ expectations of $20.44 million. Analysts forecast that Septerna will post -7.11 earnings per share for the current year.

Insider Buying and Selling at Septerna

In other news, insider Samira Shaikhly sold 70,453 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $28.10, for a total value of $1,979,729.30. Following the completion of the sale, the insider owned 793 shares of the company’s stock, valued at $22,283.30. This trade represents a 98.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Elizabeth Bhatt sold 4,000 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total value of $115,880.00. Following the transaction, the chief operating officer owned 174,209 shares in the company, valued at approximately $5,046,834.73. This trade represents a 2.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Septerna

A number of large investors have recently modified their holdings of the business. Group One Trading LLC increased its holdings in shares of Septerna by 111.8% during the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after acquiring an additional 8,955 shares in the last quarter. Global Retirement Partners LLC purchased a new position in shares of Septerna in the 4th quarter valued at approximately $35,000. Russell Investments Group Ltd. acquired a new stake in Septerna in the 3rd quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in Septerna in the 4th quarter worth approximately $53,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Septerna during the 4th quarter worth approximately $61,000.

More Septerna News

Here are the key news stories impacting Septerna this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $40.00 price target on SEPN, signaling continued analyst conviction in the company’s longer‑term upside despite the cuts. MarketBeat SEPN page
• Neutral Sentiment: Coverage roundup: a Globe and Mail piece highlights mixed analyst views on several tech names including Septerna, underscoring market disagreement about timing and magnitude of recovery. Analysts Conflicted on These Technology Names
• Neutral Sentiment: HC Wainwright published multi‑quarter 2027 EPS projections (Q1–Q4 2027 and FY2027), providing a forward framework for the next fiscal year but not materially changing the firm’s Buy stance. MarketBeat SEPN page
• Negative Sentiment: HC Wainwright cut Q1–Q4 2026 quarter estimates (Q1 to ($0.46), Q2 to ($0.55), Q3 to ($0.62), Q4 to ($0.70)), lowering FY2026 EPS to ($2.34) from ($1.67). The downward revisions widen expected near‑term losses and create pressure on sentiment. MarketBeat SEPN page

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.